185 related articles for article (PubMed ID: 3570967)
1. In vitro antibacterial properties of EL-870, a new semi-synthetic macrolide antibiotic.
Ose EE
J Antibiot (Tokyo); 1987 Feb; 40(2):190-4. PubMed ID: 3570967
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antimicrobial evaluation of 20-deoxo-20-(3,5-dimethylpiperidin-1-yl)desmycosin (tilmicosin, EL-870) and related cyclic amino derivatives.
Debono M; Willard KE; Kirst HA; Wind JA; Crouse GD; Tao EV; Vicenzi JT; Counter FT; Ott JL; Ose EE
J Antibiot (Tokyo); 1989 Aug; 42(8):1253-67. PubMed ID: 2668243
[TBL] [Abstract][Full Text] [Related]
3. Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.
McFarland JW; Hecker SJ; Jaynes BH; Jefson MR; Lundy KM; Vu CB; Glazer EA; Froshauer SA; Hayashi SF; Kamicker BJ; Reese CP; Olson JA
J Med Chem; 1997 Mar; 40(6):1041-5. PubMed ID: 9083494
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine.
Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K
J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594
[TBL] [Abstract][Full Text] [Related]
5. In vitro microbiological characterization of novel macrolide CP-163,505 for animal health specific use.
Norcia LJ; Seibel SB; Kamicker BJ; Lemay MA; Lilley SC; Hecker SJ; Bergeron JM; Retsema JA; Hayashi SF
J Antibiot (Tokyo); 1998 Feb; 51(2):136-44. PubMed ID: 9544934
[TBL] [Abstract][Full Text] [Related]
6. Postantibiotic and physiological effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens.
Diarra MS; Malouin F; Jacques M
Int J Antimicrob Agents; 1999 Aug; 12(3):229-37. PubMed ID: 10461841
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity studies of 20-deoxo-20-amino derivatives of tylosin-related macrolides.
Kirst HA; Willard KE; Debono M; Toth JE; Truedell BA; Leeds JP; Ott JL; Felty-Duckworth AM; Counter FT; Ose EE
J Antibiot (Tokyo); 1989 Nov; 42(11):1673-83. PubMed ID: 2684947
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of C-20- and C-23-modified derivatives of tylosin against veterinary pathogens.
Kirst HA; Ose EE; Toth JE; Willard KE; Debono M; Felty-Duckworth AM; Pekarek RS
J Antibiot (Tokyo); 1988 Jul; 41(7):938-48. PubMed ID: 3417566
[TBL] [Abstract][Full Text] [Related]
9. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
Blackall PJ; Asakawa T; Graydon RJ; White M; Adamson M; Wade LK; Lowe LB
Aust Vet J; 1995 Jan; 72(1):35-6. PubMed ID: 8787526
[No Abstract] [Full Text] [Related]
10. 5-O-Mycaminosyltylonolide antibacterial derivatives: design, synthesis and bioactivity.
Sugawara A; Maruyama H; Shibusawa S; Matsui H; Hirose T; Tsutsui A; Froyman R; Ludwig C; Koebberling J; Hanaki H; Kleefeld G; Ōmura S; Sunazuka T
J Antibiot (Tokyo); 2017 Jul; 70(8):878-887. PubMed ID: 28559578
[TBL] [Abstract][Full Text] [Related]
11. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella spp. associated with bovine respiratory disease.
Shryock TR; White DW; Staples JM; Werner CS
J Vet Diagn Invest; 1996 Jul; 8(3):337-44. PubMed ID: 8844577
[TBL] [Abstract][Full Text] [Related]
12. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Pasteurella haemolytica from cattle.
Stephens CP; Blackall PJ; Wade LK; Lowe LB
Aust Vet J; 1993 Oct; 70(10):391-2. PubMed ID: 8257321
[No Abstract] [Full Text] [Related]
13. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin.
Prescott JF; Yielding KM
Can J Vet Res; 1990 Jan; 54(1):195-7. PubMed ID: 2306672
[TBL] [Abstract][Full Text] [Related]
14. New amidino-benzimidazolyl derivatives of tylosin and desmycosin.
Hranjec M; Starcević K; Zamola B; Mutak S; Derek M; Karminski-Zamola G
J Antibiot (Tokyo); 2002 Mar; 55(3):308-14. PubMed ID: 12014447
[TBL] [Abstract][Full Text] [Related]
15. Single-dose treatment of neonatal calf pneumonia with the new macrolide antibiotic tilmicosin.
Ose EE; Tonkinson LV
Vet Rec; 1988 Oct; 123(14):367-9. PubMed ID: 3195026
[TBL] [Abstract][Full Text] [Related]
16. Preliminary clinical pharmacological investigations of tylosin and tiamulin in chickens.
Ziv G
Tijdschr Diergeneeskd; 1980 Oct; 105(20):206-10. PubMed ID: 7444918
[TBL] [Abstract][Full Text] [Related]
17. Postantibiotic effects and postantibiotic sub-MIC effects of erythromycin, roxithromycin, tilmicosin, and tylosin on Pasteurella multocida.
Lim J; Yun H
Int J Antimicrob Agents; 2001 Jun; 17(6):471-6. PubMed ID: 11397617
[TBL] [Abstract][Full Text] [Related]
18. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
Shryock TR; Staples JM; DeRosa DC
J Vet Diagn Invest; 2002 Sep; 14(5):389-95. PubMed ID: 12296390
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens.
Hannan PC; O'Hanlon PJ; Rogers NH
Res Vet Sci; 1989 Mar; 46(2):202-11. PubMed ID: 2704885
[TBL] [Abstract][Full Text] [Related]
20. Preparation and evaluation of 3,4''-ester derivatives of 16-membered macrolide antibiotics related to tylosin.
Kirst HA; Debono M; Willard KE; Truedell BA; Toth JE; Turner JR; Berry DR; Briggs BB; Fukuda DS; Daupert VM
J Antibiot (Tokyo); 1986 Dec; 39(12):1724-35. PubMed ID: 3818446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
